BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IRS: Boston Scientific Corporation (BSX) Owes $581 Million in Guidant Corporation (GDT) Back Taxes


12/8/2011 9:06:26 AM

Minneapolis / St. Paul Business Journal by Ed Stych, Web Producer

Boston Scientific Corp. said Wednesday the Internal Revenue Service has told the medical device maker it owes $581 million in back taxes plus interest and penalties.

The IRS's claim is based on an audit of 2004-2006 taxes of Guidant Corp., a company with a large Twin Cities presence that Boston Scientific bought for $27.5 billion in 2006.

The claim is in addition to a similar $525 million assessment made by the IRS for Guidant's 2001-2003 taxes. That claim was made a year ago and is currently being challenged by Boston Scientific in U.S. Tax Court.

The two assessments add up to more than $1.1 billion — potential liabilities incurred before Boston Scientific owned Guidant.

Natick, Mass.-based Boston Scientific (NYSE: BSX) said in a filing with the U.S. Securities and Exchange Commission

that it disagrees with the IRS' conclusions and will contest them in U.S. Tax Court. It said it won't make any payments until the courts rule on the cases.

Boston Scientific reported in the SEC filing that the primary issue with the IRS involves pricing related to the transfer of technology-license agreements between Guidant's domestic and foreign subsidiaries.

“We do not agree with the transfer-pricing methodologies applied by the IRS or its resulting assessment,” Boston Scientific said in its filing.

Guidant made defibrillators and pacemakers at its offices in Arden Hills. Boston Scientific continues to operate that facility, although the Guidant name has gone away.

The tax assessment dispute with the IRS is another event in a string of Guidant-related headaches for Boston Scientific.

In September, Boston Scientific agreed to pay the federal government $9.25 million to resolve allegations that Guidant overcharged government programs by failing to fulfill its obligations under warranties covering defibrillators and pacemakers.

In January of this year, a federal judge approved a deal for Boston Scientific to pay $296 million to settle federal charges that Guidant failed to report faulty defibrillators. The defects were associated with at least 13 deaths.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES